Apricot Capital
Funding rounds backed by Apricot Capital.
- Funding disclosed in full
- $192.7M
- Median round
- $52M
- Rounds in calculation
- 4
| Company | Round | Market | Investors | Announced | Details |
|---|---|---|---|---|---|
| Vivacta Biotechnology Develops in vivo CAR-T cell therapies for cancer and autoimmune diseases | $50MSeries A+ | BiotechChina | |||
| Vivatides Therapeutics Develops extrahepatic RNA-targeting therapeutics | $54MSeries A | BiotechChina | |||
| Excalipoint Therapeutics Develops next-generation T-cell engager therapies for cancer and autoimmune diseases | $27.7MSeed+ | BiotechChina | |||
| Vibrant Therapeutics Develops intelligent, logic-gated therapeutics for solid tumors | $61MSeries A | BiotechChina |